Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study

Bachetti, Tiziana; Bardile, Alberto Ferrari; Aloi, Teresa Lucia; Colombo, Barbara; Assi, Emma; Savino, Giuseppina; Vercelli, Alessandro; Colombo, Roberto; Corti, Angelo

doi:10.1016/j.ijcard.2017.02.019

Cited by 11 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an emerging gene editing tool, the CRISPR/Cas9 system based on the aggregation of regularly spaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9), which is with high efficiency and specificity, and has been widely used in molecular fields such as gene editing, correction of pathogenic genes, verification of functional genes, and treatment of genetic diseases [ 8 ]. However, the large size of CRISPR/Cas9 limits its development process due to its in vivo delivery [ 9 ]. Although a variety of CRISPR/Cas9 system delivery vectors have been applied in tumor diseases, their application in aortic aneurysm has been minimal.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Protective effect of vasostatin-1 plasmid-like nanoparticles on aortic aneurysm and its mechanism

Wang

Peng

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Vasostatin 1 (VS-1) plays an important role in the regulation of various tissue injury and repair processes, but its role in aortic aneurysm remains unclear. The plasmid-like nanoparticles containing the vasostatin-1 gene Pul-PGEA-pCas-sgVs-1 were constructed, and their guarantee, safety, hemolysis, and particle size were analyzed. Eighty-four eight-week-old male ApoE-mice were randomly divided into blank group (without any treatment), model group (Ang II aortic aneurysm model + tail injection of PBS), control group (modeling + tail injection of Pul-PGEA-pCas9), and experimental group (modeling + tail injection of Pul-PGEA-pCas-sgVs-1), with 21 rats in each group. The incidence, mortality, and maximum diameter of abdominal aortic aneurysm (AAA) and the contents of high sensitivity C-reactive protein (HS-CRP), soluble intercellular adhesion molecule-1 (ICAM-1), soluble vascular cell adhesion molecule-1 (VCAM-1), and TNF-a in serum were compared in different groups of mice. The results showed that Pul-PGEA-pCas-sgVs-1 had good biosafety and transfection ability. The maximum diameter of abdominal aorta, incidence of abdominal aortic aneurysm, mortality, and the expression levels of HS-CRP, ICAM-1, VCAM-1, and TNF-a in the experimental group were lower than those in the model group ( P < 0.05). These results indicated that the plasmid-like nanoparticles Pul-PGEA-pCas-sgVs-1 can inhibit the development of aorta by down-regulating the expression of inflammatory factors, which played a good protective role on the aorta.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Protective effect of vasostatin-1 plasmid-like nanoparticles on aortic aneurysm and its mechanism

Wang

Peng

et al. 2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…In CAD patients, plasma CgA levels rise even higher in the presence of heart failure [ 55 ]. Plasma levels of vasostatin-1 are positively associated with carotid atherosclerosis [ 56 ]. In contrast, circulating levels of vasostatin-2 and catestatin are significantly decreased in patients with CAD compared with healthy control groups of patients [ 19 , 50 , 57 , 58 ] ( Table 2 ).…”

Section: Biomarker For Diabetes Metabolic Syndrome and Cardiovascular Diseasementioning

confidence: 99%

The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease

Watanabe

2021

IJMS

View full text Add to dashboard Cite

Chromogranin A (CgA), B (CgB), and C (CgC), the family members of the granin glycoproteins, are associated with diabetes. These proteins are abundantly expressed in neurons, endocrine, and neuroendocrine cells. They are also present in other areas of the body. Patients with diabetic retinopathy have higher levels of CgA, CgB, and CgC in the vitreous humor. In addition, type 1 diabetic patients have high CgA and low CgB levels in the circulating blood. Plasma CgA levels are increased in patients with hypertension, coronary heart disease, and heart failure. CgA is the precursor to several functional peptides, including catestatin, vasostatin-1, vasostatin-2, pancreastatin, chromofungin, and many others. Catestatin, vasostain-1, and vasostatin-2 suppress the expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular endothelial cells. Catestatin and vasostatin-1 suppress oxidized low-density lipoprotein-induced foam cell formation in human macrophages. Catestatin and vasostatin-2, but not vasostatin-1, suppress the proliferation and these three peptides suppress the migration in human vascular smooth muscles. Chronic infusion of catestatin, vasostatin-1, or vasostatin-2 suppresses the development of atherosclerosis of the aorta in apolipoprotein E-deficient mice. Catestatin, vasostatin-1, vasostatin-2, and chromofungin protect ischemia/reperfusion-induced myocardial dysfunction in rats. Since pancreastatin inhibits insulin secretion from pancreatic β-cells, and regulates glucose metabolism in liver and adipose tissues, pancreastatin inhibitor peptide-8 (PSTi8) improves insulin resistance and glucose homeostasis. Catestatin stimulates therapeutic angiogenesis in the mouse hind limb ischemia model. Gene therapy with secretoneurin, a CgC-derived peptide, stimulates postischemic neovascularization in apolipoprotein E-deficient mice and streptozotocin-induced diabetic mice, and improves diabetic neuropathy in db/db mice. Therefore, CgA is a biomarker for atherosclerosis, diabetes, hypertension, and coronary heart disease. CgA- and CgC--derived polypeptides provide the therapeutic target for atherosclerosis and ischemia-induced tissue damages. PSTi8 is useful in the treatment of diabetes.

show abstract

“…One study noted plasma levels of VS-1 and total-CgA significantly correlated with carotid artery maximum stenosis, and regression analysis indicated it was a predictor of maximum stenosis even after adjustment of confounders. They also noted higher levels of CgA1-439 were predictive of hypoechogenic plaque (i.e., plaques with higher levels of fibrous tissue and calcification), which has been associated with higher risk of adverse events [ 34 , 172 , 173 ].…”

Section: Protein Categorizationmentioning

confidence: 99%

Current Biomarkers for Carotid Artery Stenosis: A Comprehensive Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Carotid artery stenosis (CAS), an atherosclerotic disease of the carotid artery, is one of the leading causes of transient ischemic attacks (TIA) and cerebrovascular attacks (CVA). The atherogenic process of CAS affects a wide range of physiological processes, such as inflammation, endothelial cell function, smooth muscle cell migration and many more. The current gold-standard test for CAS is Doppler ultrasound; however, there is yet to be determined a strong, clinically validated biomarker in the blood that can diagnose patients with CAS and/or predict adverse outcomes in such patients. In this comprehensive literature review, we evaluated all of the current research on plasma and serum proteins that are current contenders for biomarkers for CAS. In this literature review, 36 proteins found as potential biomarkers for CAS were categorized in to the following nine categories based on protein function: (1) Inflammation and Immunity, (2) Lipid Metabolism, (3) Haemostasis, (4) Cardiovascular Markers, (5) Markers of Kidney Function, (6) Bone Health, (7) Cellular Structure, (8) Growth Factors, and (9) Hormones. This literature review is the most up-to-date and current comprehensive review of research on biomarkers of CAS, and the only review that demonstrated the several pathways that contribute to the initiation and progression of the disease. With this review, future studies can determine if any new markers, or a panel of the proteins explored in this study, may be contenders as diagnostic or prognostic markers for CAS.

show abstract

Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study

Cited by 11 publications

References 38 publications

RETRACTED ARTICLE: Protective effect of vasostatin-1 plasmid-like nanoparticles on aortic aneurysm and its mechanism

RETRACTED ARTICLE: Protective effect of vasostatin-1 plasmid-like nanoparticles on aortic aneurysm and its mechanism

The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease

Current Biomarkers for Carotid Artery Stenosis: A Comprehensive Review of the Literature

Contact Info

Product

Resources

About